Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively blocks BCR‑ABL, c‑KIT and PDGFR signaling and is indicated for the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance through reliable logistics and support.

Nilotinib is a targeted therapy used in the management of BCR‑ABL‑positive leukemias.

- Chronic Myeloid Leukemia (CML): provides disease control across chronic, accelerated, and blast phases. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): enables remission induction and maintenance in adult patients. - Imatinib‑resistant CML: offers an alternative targeted option after prior tyrosine kinase inhibitor therapy.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Fatigue: general tiredness.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Pancreatitis: abdominal pain with elevated enzymes. - Severe hepatotoxicity: marked liver enzyme elevation or hepatitis.

When prescribing Nilotinib, clinicians should observe several safety considerations.

- Cardiac monitoring: assess QT interval and correct electrolyte abnormalities. - Hepatic function: monitor liver enzymes regularly. - Pancreatic enzymes: check amylase and lipase during therapy. - Concomitant QT‑prolonging drugs: avoid or use with caution. - Renal impairment: adjust dose or monitor renal function as needed. - Store at ambient temperature: keep in the original container, protect from moisture.

Nilotinib is metabolized primarily by CYP3A4, leading to potential drug‑drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nilotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids containing aluminum or magnesium: can impair absorption. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of arrhythmia. - St. John's wort: may lower plasma concentrations.

Moderate Interactions (Monitor Closely): - Digoxin: may require serum level monitoring. - Warfarin: monitor INR for potential anticoagulation changes.